EGFR+ Lung Cancer | Clinical

Amivantamab and Lazertinib as a Potential Option for EGFR-Mutant NSCLC

February 01, 2023

Alexander Spira, MD, PhD, FACP, discusses osimertinib-relapsed disease and its sensitivity to EGFR or MET inhibition.

China’s NMPA to Review NDA of Zorifertinib for EGFR-Mutated NSCLC With CNS Metastases

January 30, 2023

The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.

FDA Accepts IND for HT-001 for EGFRi-Associated Rash and Skin Disorders

January 17, 2023

Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.

Piotrowska Looks at Amivantamab and Mobocertinib for Patients With Rare Driver Mutations in NSCLC

January 16, 2023

During a Targeted Oncology case-based roundtable event, Zofia Piotrowska, MD, MHS, discussed molecular testing for actionable mutations and recommended treatments for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

Practice Changing Updates in the EGFR+ and KRAS+ NSCLC Space

January 05, 2023

Andreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.

Key Takeaways From a Trial of Erlotinib/Binimetinib in EGFR+ or KRAS+ NSCLC

December 16, 2022

Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.

Participant Perceptions: Treating NSCLC in the Community Setting

December 15, 2022

After participating in a Case-Based Roundtable event led by Gavitt Woodward, MD, M. Sheila Donnelly, MD, spoke with Targeted Oncology about the patients with lung cancer she treats.

Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC

December 05, 2022

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.

Tepotinib and Gefitinib Show Long OS in EGFR+ NSCLC With MET Amplification

November 25, 2022

Tepotinib plus gefitinib led to improvements in progression-free survival and overall survival in patients with EGFR-mutant non–small cell lung cancer.

Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC

November 21, 2022

During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.